tiprankstipranks
Advertisement
Advertisement

RANI Stock Latest News

Rani Therapeutics Rated Buy as Analyst Highlights RT-114 Progress, Chugai Partnership and Cash Runway; $11 Price Target Reiterated
RatingsRani Therapeutics Rated Buy as Analyst Highlights RT-114 Progress, Chugai Partnership and Cash Runway; $11 Price Target Reiterated
3d ago
RANI
Rani Therapeutics Shareholders Back Board and Auditor at Meeting
PremiumCompany Announcements
Rani Therapeutics Shareholders Back Board and Auditor at Meeting
6d ago
8K
RANI
Rani Therapeutics Announces $20 Million Equity Financing
PremiumCompany Announcements
Rani Therapeutics Announces $20 Million Equity Financing
8d ago
8K
RANI
Nasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid Price
PremiumCompany Announcements
Nasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid Price
18d ago
RANI
Rani Therapeutics Faces Nasdaq Bid Price Noncompliance Notice
PremiumCompany Announcements
Rani Therapeutics Faces Nasdaq Bid Price Noncompliance Notice
20d ago
8K
RANI
Rani Therapeutics CFO Svai Sanford to step down
PremiumThe FlyRani Therapeutics CFO Svai Sanford to step down
20d ago
RANI
Rani Therapeutics reports Q1 EPS (4c), consensus (5c)
Premium
The Fly
Rani Therapeutics reports Q1 EPS (4c), consensus (5c)
20d ago
RANI
Edward Nash Reiterates Buy on Rani Therapeutics, Maintains Unchanged $5 Price Target Amid Encouraging RT-114 and Oral Biologics Platform Outlook
Premium
Ratings
Edward Nash Reiterates Buy on Rani Therapeutics, Maintains Unchanged $5 Price Target Amid Encouraging RT-114 and Oral Biologics Platform Outlook
28d ago
RANI
Rani Therapeutics price target lowered to $5 from $9 at Canaccord
PremiumThe Fly
Rani Therapeutics price target lowered to $5 from $9 at Canaccord
2M ago
RANI
Rani Therapeutics reports Q4 EPS (7c), consensus (7c)
PremiumThe Fly
Rani Therapeutics reports Q4 EPS (7c), consensus (7c)
2M ago
RANI
Rani Therapeutics Holdings options imply 17.3% move in share price post-earnings
PremiumThe Fly
Rani Therapeutics Holdings options imply 17.3% move in share price post-earnings
2M ago
RANI
RANI Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
RANI Upcoming Earnings Report: What to Expect?
2M ago
RANI
Rani Therapeutics promotes Javadi to Chief Technical Officer
PremiumThe FlyRani Therapeutics promotes Javadi to Chief Technical Officer
4M ago
RANI
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
4M ago
IBN
LQD
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
4M ago
BARK
CBRL
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
5M ago
RR
ENB
Rani Therapeutics initiates Phase 1 study of RT-114 RaniPill
PremiumThe Fly
Rani Therapeutics initiates Phase 1 study of RT-114 RaniPill
5M ago
RANI
Rani Therapeutics finalizes governance and capital structure changes
PremiumCompany Announcements
Rani Therapeutics finalizes governance and capital structure changes
5M ago
8K
RANI
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
5M ago
CGC
SLS
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
6M ago
S
BRR
Rani Therapeutics files to sell 42.63M shares of Class A common stock for holder
Premium
The Fly
Rani Therapeutics files to sell 42.63M shares of Class A common stock for holder
7M ago
RANI
Rani Therapeutics Reports Financial Challenges Amid Innovation
Premium
Company Announcements
Rani Therapeutics Reports Financial Challenges Amid Innovation
7M ago
RANI

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >